Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Yuya Hirasawa

TitlePost-Doctoral Fellow
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-SRG

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Yamashita T, Fujimasa K, Otsuka K, Saito A, Kohmoto M, Motegi K, Ariyoshi T, Goto S, Yamochi T, Takimoto M, Hirasawa Y, Kubota Y, Yoshimura K, Tsunoda T, Murakami M, Aoki T. Efficacy of Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Neuroendocrine Carcinoma. Anticancer Res. 2025 May; 45(5):2051-2058. PMID: 40295050.
      View in: PubMed
    2. Tsurui T, Hosonuma M, Sasaki A, Maruyama Y, Amari Y, Funayama E, Tajima K, Toyoda H, Isobe J, Yamazaki Y, Baba Y, Shida M, Udaka Y, Mura E, Suzuki R, Iriguchi N, Ishiguro T, Hirasawa Y, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Wada S, Kuramasu A, Tsuji M, Kiuchi Y, Tsunoda T, Yoshimura K. Ki-67 expression in anti-programmed cell death protein-1 antibody-bound CD8+ T cells as a predictor of clinical benefit. Discov Oncol. 2025 Mar 18; 16(1):348. PMID: 40100476.
      View in: PubMed
    3. Tsurui T, Hamada K, Mura E, Suzuki R, Iriguchi N, Ishiguro T, Hirasawa Y, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Wada S, Yoshimura K, Tsuji M, Kiuchi Y, Tsunoda T. Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study. Front Oncol. 2025; 15:1499650. PMID: 39980541.
      View in: PubMed
    4. Ishiguro T, Takeda K, Takayanagi D, Mura E, Suzuki R, Tsurui T, Iriguchi N, Hirasawa Y, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Izumizaki M, Wada S, Yoshimura K, Hoffman RM, Tsunoda T. Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors. Cancer Genomics Proteomics. 2025 Jan-Feb; 22(1):1-12. PMID: 39730175.
      View in: PubMed
    5. Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Yamashita T, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Tsunoda T. Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients. Front Oncol. 2024; 14:1449941. PMID: 39464714.
      View in: PubMed
    6. Toyoda H, Kuramasu A, Hosonuma M, Murayama M, Narikawa Y, Isobe J, Baba Y, Tajima K, Funayama E, Shida M, Maruyama Y, Sasaki A, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Kobayashi S, Horiike A, Hida N, Sambe T, Nobe K, Wada S, Kobayashi H, Tsuji M, Kobayashi S, Tsunoda T, Kudo Y, Kiuchi Y, Yoshimura K. MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2DLow T cells. Sci Rep. 2024 10 08; 14(1):23401. PMID: 39379424.
      View in: PubMed
    7. Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Hoffman RM, Tsunoda T. Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment. Anticancer Res. 2024 Aug; 44(8):3397-3407. PMID: 39060084.
      View in: PubMed
    8. Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, Narikawa Y, Toyoda H, Isobe J, Funayama E, Tajima K, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Hamada K, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kobayashi S, Shimane T, Tsunoda T, Kobayashi H, Kiuchi Y, Yoshimura K. Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody. Sci Rep. 2024 05 17; 14(1):11325. PMID: 38760458.
      View in: PubMed
    9. Tsurui T, Hirasawa Y, Kubota Y, Yoshimura K, Tsunoda T. Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report. World J Gastrointest Oncol. 2024 Feb 15; 16(2):557-562. PMID: 38425406.
      View in: PubMed
    10. Otsuka K, Isobe J, Asai Y, Nakano T, Hattori K, Ariyoshi T, Yamashita T, Motegi K, Saito A, Kohmoto M, Hosonuma M, Kuramasu A, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Horiike A, Goto S, Murakami M, Kim YG, Tsunoda T, Yoshimura K. Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer. Cancer Immunol Immunother. 2024 Jan 27; 73(2):23. PMID: 38280026.
      View in: PubMed
    11. Hosonuma M, Hirasawa Y, Kuramasu A, Murayama M, Narikawa Y, Toyoda H, Baba Y, Isobe J, Funayama E, Tajima K, Shida M, Hamada K, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Tsunoda T, Yoshimura K. Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit. Cancer Sci. 2024 Mar; 115(3):752-762. PMID: 38254257.
      View in: PubMed
    12. Goshima T, Ieguchi K, Onishi N, Shimizu T, Takayanagi D, Watanabe M, Fujimoto Y, Ohkuma R, Suzuki R, Tsurui T, Mura E, Iriguchi N, Ishiguro T, Shimokawa M, Hirasawa Y, Kubota Y, Ariizumi H, Horiike A, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Fujishiro J, Hoffman RM, Tsunoda T, Wada S. Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model. Anticancer Res. 2024 Jan; 44(1):23-29. PMID: 38159965.
      View in: PubMed
    13. Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S. Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors. Front Immunol. 2023; 14:1260492. PMID: 37790929.
      View in: PubMed
    14. Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Sasaki Y, Homma M, Yamochi T, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Monocyte subsets associated with the efficacy of anti-PD-1 antibody monotherapy. Oncol Lett. 2023 Sep; 26(3):381. PMID: 37559573.
      View in: PubMed
    15. Suzuki R, Hamada K, Ohkuma R, Homma M, Tsurui T, Iriguchi N, Ishiguro T, Hirasawa Y, Ariizumi H, Kubota Y, Horiike A, Yoshimura K, Wada S, Yamochi T, Tsunoda T. Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary. Front Oncol. 2023; 13:1231986. PMID: 37496666.
      View in: PubMed
    16. Hamada K, Isobe J, Hattori K, Hosonuma M, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Kuramasu A, Horiike A, Kim YG, Tsunoda T, Yoshimura K. Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor. Front Immunol. 2023; 14:1164724. PMID: 37207204.
      View in: PubMed
    17. Hamada K, Yoshimura K, Oshinomi K, Hirasawa Y, Ariizumi H, Ohkuma R, Shida M, Kubota Y, Matsui H, Ishiguro T, Sambe T, Ishida H, Horiike A, Wada S, Iwamoto S, Uchida N, Ogawa Y, Kobayashi S, Tsunoda T. A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report. Medicine (Baltimore). 2022 Jan 14; 101(2):e28339. PMID: 35029177.
      View in: PubMed
    18. Ohkuma R, Ieguchi K, Watanabe M, Takayanagi D, Goshima T, Onoue R, Hamada K, Kubota Y, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Tsurutani J, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies. Biomedicines. 2021 Dec 16; 9(12). PMID: 34944745.
      View in: PubMed
    19. Hamada K, Yoshimura K, Hirasawa Y, Hosonuma M, Murayama M, Narikawa Y, Ariizumi H, Ohkuma R, Shida M, Kubota Y, Matsukuma S, Ishiguro T, Sambe T, Horiike A, Kuramasu A, Wada S, Tsurutani J, Inoue E, Uchida N, Kiuchi Y, Kobayashi S, Hoffman RM, Tsunoda T. Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy. Anticancer Res. 2021 Oct; 41(10):4985-4993. PMID: 34593446.
      View in: PubMed
    20. Tsuboya A, Kubota Y, Ishida H, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Sasaki Y, Matsumoto N, Kondo Y, Tomoda Y, Kusuhara H, Fujita KI. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure. Cancer Chemother Pharmacol. 2021 09; 88(3):543-553. PMID: 34117512.
      View in: PubMed
    21. Hirasawa Y, Yoshimura K, Matsui H, Kubota Y, Ishida H, Arai J, Sakaki M, Oguro N, Shida M, Taniguchi M, Hamada K, Ariizumi H, Ishiguro T, Ohkuma R, Sambe T, Horiike A, Imamura CK, Shiozawa E, Wada S, Tsurutani J, Iwamoto S, Uchida N, Kiuchi Y, Tate G, Kobayashi S, Tsunoda T. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine (Baltimore). 2021 Jun 11; 100(23):e25774. PMID: 34114983.
      View in: PubMed
    22. Miyazaki K, Hirasawa Y, Aga M, Aiko N, Hamakawa Y, Taniguchi Y, Misumi Y, Agemi Y, Shimokawa T, Hayashi H, Naoki K, Okamoto H. Examination of endobronchial ultrasound-guided transbronchial needle aspiration using a puncture needle with a side trap. Sci Rep. 2021 05 07; 11(1):9789. PMID: 33963234.
      View in: PubMed
    23. Kubota Y, Yoshimura K, Hamada K, Hirasawa Y, Shida M, Taniguchi M, Matsui H, Ariizumi H, Ishiguro T, Suzuki N, Ohkuma R, Sambe T, Ishida H, Horiike A, Wada S, Tsurutani J, Iwamoto S, Uchida N, Kiuchi Y, Kobayashi S, Tsunoda T. Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer. In Vivo. 2021 May-Jun; 35(3):1865-1875. PMID: 33910874.
      View in: PubMed
    24. Ohkuma R, Kubota Y, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Aoki T, Murakami M, Kobayashi S, Tsunoda T, Wada S. The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer. Pancreas. 2021 02 01; 50(2):167-175. PMID: 33565793.
      View in: PubMed
    25. Ohkuma R, Yada E, Ishikawa S, Komura D, Kubota Y, Hamada K, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Kobayashi S, Tsunoda T, Wada S. High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer. Int J Oncol. 2021 01; 58(1):57-69. PMID: 33367933.
      View in: PubMed
    26. Ando K, Hamada K, Shida M, Ohkuma R, Kubota Y, Horiike A, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Watanabe M, Onoue R, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S. A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother. 2021 Feb; 70(2):337-348. PMID: 32757055.
      View in: PubMed
    27. Matsumoto N, Kubota Y, Ishida H, Sekido M, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Ikusue T, Kobayashi K, Hisamatsu A, Toshima H, Shimada K, Fujita KI. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients. Cancer Chemother Pharmacol. 2020 06; 85(6):1119-1128. PMID: 32458030.
      View in: PubMed
    28. Ohkuma R, Yada E, Ishikawa S, Komura D, Kubota Y, Hamada K, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Kobayashi S, Tsunoda T, Wada S. High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer. Oncol Rep. 2020 07; 44(1):252-262. PMID: 32627041.
      View in: PubMed
    29. Ohkuma R, Yada E, Ishikawa S, Komura D, Ishizaki H, Tamada K, Kubota Y, Hamada K, Ishida H, Hirasawa Y, Ariizumi H, Satoh E, Shida M, Watanabe M, Onoue R, Ando K, Tsurutani J, Yoshimura K, Yokobori T, Sasada T, Aoki T, Murakami M, Norose T, Ohike N, Takimoto M, Izumizaki M, Kobayashi S, Tsunoda T, Wada S. High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. PLoS One. 2020; 15(1):e0226707. PMID: 31923206.
      View in: PubMed
    30. Ando K, Hamada K, Watanabe M, Ohkuma R, Shida M, Onoue R, Kubota Y, Matsui H, Ishiguro T, Hirasawa Y, Ariizumi H, Tsurutani J, Yoshimura K, Tsunoda T, Kobayashi S, Wada S. Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors. Anticancer Res. 2019 Sep; 39(9):5195-5201. PMID: 31519633.
      View in: PubMed
    Hirasawa's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (128) concept(s)
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)